Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 5Neoplasms by Histologic Type 4Neoplasms 4Myeloproliferative Disorders 4Leukemia, Myeloid 4Hematologic Diseases 4Bone Marrow Diseases 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Chronic-Phase 3Lymphoproliferative Disorders 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Blast Crisis 1

Interventions

ponatinib 1Vincristine 1Prednisone 1Methotrexate 1Imatinib Mesylate 1Dexamethasone 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) × ponatinib × Clear all
NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Takeda

Phase 3 Active not recruiting
245 enrolled 15 charts 1 FDA
LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡